Oppenheimer upgraded Enhabit to Outperform from Perform with a $14 price target. The firm believes the post-acute care group is benefiting from "major tailwinds," including strong demand, a more stable regulatory environment, and improving labor trends. Enhabit is positioned to benefit from an improved reimbursement outlook, the analyst tells investors in a research note. In addition, Oppenheimer says the company's operational initiatives should drive the business going forward.
